Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-cell multi-omics reveal stage of differentiation and trajectory-dependent immunity-related gene expression patterns in human erythroid cells. | Front Immunol | 2024 | 39267736 | PubTator, text mining | PubMed |
| A functional role for glycosylated B7-H5/VISTA immune checkpoint protein in metastatic clear cell renal cell carcinoma. | iScience | 2024 | 39262813 | PubTator, text mining | PubMed |
| Coinhibitory Molecule VISTA Play an Important Negative Regulatory Role in the Immunopathology of Bronchial Asthma. | J Asthma Allergy | 2024 | 39246611 | PubTator, text mining | PubMed |
| Abstracts Presented at the 2024 WIN Symposium in Partnership with Burjeel Holdings: March 1-2, 2024, Abu Dhabi, United Arab Emirates. | J Immunother Precis Oncol | 2024 | 39219997 | PubTator, text mining | PubMed |
| Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth. | Cancers (Basel) | 2024 | 39199551 | PubTator, text mining | PubMed |
| Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993. | Eur J Nucl Med Mol Imaging | 2024 | 39186103 | PubTator, text mining | PubMed |
| VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma. | Cancers (Basel) | 2024 | 39123357 | PubTator, text mining | PubMed |
| Inhibition of Tumoral VISTA to Overcome TKI Resistance via Downregulation of the AKT/mTOR and JAK2/STAT5 Pathways in Chronic Myeloid Leukemia. | Biomol Ther (Seoul) | 2024 | 39104205 | PubTator, text mining | PubMed |
| Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments. | Int Immunopharmacol | 2024 | 39079196 | PubTator, text mining | PubMed |
| Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993. | Eur J Nucl Med Mol Imaging | 2024 | 39060374 | PubTator, text mining | PubMed |
| Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy. | Sci Adv | 2024 | 39028818 | PubTator, text mining | PubMed |
| BSG Isoform 2 (ENST00000353555) Is a Better Component Than Total BSG Expression in Generating Prognostic Signature for Overall Survival of Liver Cancer. | Cureus | 2024 | 39006665 | PubTator, text mining | PubMed |
| Differential Immune Checkpoint Protein Expression in HNSCC: The Role of HGF/MET Signaling. | Int J Mol Sci | 2024 | 39000441 | PubTator, text mining | PubMed |
| VISTA: A promising target for overcoming immune evasion in gynecologic cancers. | Int Immunopharmacol | 2024 | 38986302 | PubTator, text mining | PubMed |
| CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression. | Blood Adv | 2024 | 38959399 | PubTator, text mining | PubMed |
| Single-cell RNA-Seq analysis reveals cell subsets and gene signatures associated with rheumatoid arthritis disease activity. | JCI Insight | 2024 | 38954480 | PubTator, text mining | PubMed |
| Multiplexed Spatial Profiling of Hodgkin Reed-Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma. | Clin Cancer Res | 2024 | 38949890 | PubTator, text mining | PubMed |
| Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets. | Biochim Biophys Acta Rev Cancer | 2024 | 38914239 | PubTator, text mining | PubMed |
| VISTA Deficiency Exacerbates the Development of Pulmonary Fibrosis by Promoting Th17 Differentiation. | J Inflamm Res | 2024 | 38911987 | PubTator, text mining | PubMed |
| VISTA antibody-loaded Fe3O4@TiO2 nanoparticles for sonodynamic therapy-synergistic immune checkpoint therapy of pancreatic cancer. | Mater Today Bio | 2024 | 38883421 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=12